Compositions and methods of promoting wound healing

Abstract

A method of treating a wound in a subject includes administering directly to the wound or an area proximate the wound an amount of SDF-I effective to promote healing of the wound of the subject.

1 . A method for promoting wound healing in a subject, comprising:
 administering directly to the wound or an area proximate the wound an amount of SDF-1 effective to promote healing of the wound of the subject and increase Akt-phosphorylation in cells expressing SDF-1 receptors of the wound or proximate the wound.   
     
     
         2 . (canceled) 
     
     
         3 . The method of  claim 1 , the SDF-1 receptor comprising CXCR4 and/or CXCR7. 
     
     
         4 . (canceled) 
     
     
         5 . The method of  claim 1 , the SDF-1 being administered by expressing or promoting expression of SDF-1 from a cell proximate the wound. 
     
     
         6 . The method of  claim 5 , the cell expressing the SDF-1 being genetically modified by at least one of a vector, plasmid DNA, electroporation, and nano-particles to express SDF-1. 
     
     
         7 . The method of  claim 5 , the expression of SDF-1 being promoted by administering a cytokine to the cell. 
     
     
         8 . The method of  claim 7 , the cytokine being selected from the group consisting of insulin-like growth factor (IGF)-1, sonic hedgehog (Shh), transforming growth factor β (TGF-β), IL-1β, PDG-BF, VEGF, TNF-α, PTH, thymosin β4, and hypoxia inducible factor 1α (HIF-1). 
     
     
         9 . The method of  claim 1 , the SDF-1 being administered in a topical and/or local formulation that is administered directly to the wound. 
     
     
         10 . The method of  claim 9 , the topical and/or local formulation comprising at least one of SDF-1 protein or an SDF-1 vector for expressing SDF-1 from cells of the wound or proximate the wound. 
     
     
         11 . The method of  claim 10 , the topical and/or local formulation being administered to an acute wound. 
     
     
         12 . The method of  claim 11 , the topical and/or local formulation being administered to a chronic wound. 
     
     
         13 . A method for accelerating wound closure in a subject, comprising:
 administering directly to the wound or an area proximate the wound an amount of SDF-1 effective to accelerate closure of the wound of the subject and increase Akt-phosphorylation in cells expressing SDF-1 receptors of the wound or proximate the wound.   
     
     
         14 . (canceled) 
     
     
         15 . The method of  claim 13 , the SDF-1 receptor comprising CXCR4 and/or CXCR7. 
     
     
         16 . (canceled) 
     
     
         17 . The method of  claim 13 , the SDF-1 being administered by expressing or promoting expression of SDF-1 from a cell proximate the wound. 
     
     
         18 . The method of  claim 17 , the cell expressing the SDF-1 being genetically modified by at least one of a vector, plasmid DNA, electroporation, and nano-particles to express SDF-1. 
     
     
         19 . The method of  claim 17 , the expression of SDF-1 being promoted by administering a cytokine to the cell. 
     
     
         20 . The method of  claim 19 , the cytokine being selected from the group consisting of insulin-like growth factor (IGF)-1, sonic hedgehog (Shh), transforming growth factor β (TGF-β), IL-1β, PDG-BF, VEGF, TNF-α, PTH, thymosin β4, and hypoxia inducible factor 1α (HIF-1). 
     
     
         21 . The method of  claim 13 , the SDF-1 being administered in a topical and/or local formulation that is administered directly to the wound. 
     
     
         22 . The method of  claim 21 , the topical and/or local formulation comprising at least one of SDF-1 protein or an SDF-1 vector for expressing SDF-1 from cells of the wound or proximate the wound. 
     
     
         23 . The method of  claim 21 , the topical and/or local formulation being administered to an acute wound. 
     
     
         24 . The method of  claim 21 , the topical and/or local formulation being administered to a chronic wound. 
     
     
         25 . A method of mitigating scar formation during healing of a wound of a subject, comprising:
 administering directly to the wound or an area proximate the wound an amount of SDF-1 effective to inhibit formation of fibrosis in the wound of the subject and increase Akt-phosphorylation in cells expressing SDF-1 receptors of the wound or proximate the wound.   
     
     
         26 . (canceled) 
     
     
         27 . The method of  claim 25 , the SDF-1 being administered by expressing or promoting expression of SDF-1 from a cell proximate the wound. 
     
     
         28 . The method of  claim 27 , the cell expressing the SDF-1 being genetically modified by at least one of a vector, plasmid DNA, electroporation, and nano-particles to express SDF-1. 
     
     
         29 . The method of  claim 25 , the SDF-1 being administered in a topical and/or local formulation that is administered directly to the wound. 
     
     
         30 . The method of  claim 29 , the topical and/or local formulation comprising at least one of SDF-1 protein or an SDF-1 vector for expressing SDF-1 from cells of the wound or proximate the wound. 
     
     
         31 . The method of  claim 29 , the topical and/or local formulation being administered to an acute wound. 
     
     
         32 . The method of  claim 29 , the topical and/or local formulation being administered to a chronic wound. 
     
     
         33 - 38 . (canceled) 
     
     
         39 . A topical formation for treating a wound, the topical formulation comprising:
 at least one of a therapeutically effective amount of an SDF-1 protein or an SDF-1 plasmid and at least one carrier, the topical formulation when administered to a wound of a subject promoting wound healing, accelerating wound closure, and/or inhibiting formation of scar tissue in the wound.